Celltrion Healthcare Future Growth

Future criteria checks 4/6

Celltrion Healthcare is forecast to grow earnings and revenue by 63.3% and 17.2% per annum respectively. EPS is expected to grow by 62.7% per annum. Return on equity is forecast to be 13.7% in 3 years.

Key information

63.3%

Earnings growth rate

62.7%

EPS growth rate

Healthcare earnings growth	19.0%
Revenue growth rate	17.2%
Future return on equity	13.7%
Analyst coverage	Good
Last updated	12 Jan 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

KOSDAQ:A091990 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	3,243,700	371,178	109,667	203,533	9
12/31/2024	2,796,111	276,422	169,633	290,500	9
12/31/2023	2,335,125	166,067	38,000	-14,550	4
9/30/2023	2,218,023	43,133	125,162	130,923	N/A
6/30/2023	2,066,847	135,951	-42,286	-38,061	N/A
3/31/2023	2,060,053	157,644	210,387	212,159	N/A
12/31/2022	1,972,188	147,178	200,533	202,119	N/A
9/30/2022	2,036,930	237,067	81,334	85,204	N/A
6/30/2022	1,949,646	140,048	108,060	122,236	N/A
3/31/2022	1,863,891	164,644	-180,959	-158,041	N/A
12/31/2021	1,804,486	152,567	-198,120	-175,312	N/A
9/30/2021	1,585,653	167,523	-161,698	-141,655	N/A
6/30/2021	1,639,954	213,010	-203,646	-191,967	N/A
3/31/2021	1,626,987	195,722	-61,689	-58,698	N/A
12/31/2020	1,627,597	240,407	-25,605	-22,608	N/A
9/30/2020	1,554,163	249,216	-156,588	-153,565	N/A
6/30/2020	1,372,783	173,262	-200,974	-200,156	N/A
3/31/2020	1,237,266	135,315	-192,454	-191,682	N/A
12/31/2019	1,100,878	64,962	-164,433	-163,839	N/A
9/30/2019	976,014	-42,023	-128,387	-128,208	N/A
6/30/2019	906,649	-45,782	37,692	38,023	N/A
3/31/2019	805,635	-43,278	-83,143	-82,781	N/A
12/31/2018	713,487	11,386	-185,406	-184,228	N/A
9/30/2018	989,193	175,707	-192,348	-190,910	N/A
6/30/2018	945,767	178,499	-349,535	-347,847	N/A
3/31/2018	991,440	238,447	-254,164	-252,306	N/A
12/31/2017	921,500	165,684	-195,744	-194,300	N/A
9/30/2017	872,771	136,604	31,026	32,163	N/A
6/30/2017	876,929	167,562	N/A	71,717	N/A
3/31/2017	741,590	94,037	N/A	97,949	N/A
12/31/2016	756,437	123,503	N/A	30,436	N/A
12/31/2015	376,033	-6,740	N/A	32,010	N/A
12/31/2014	166,549	10,133	N/A	-248,247	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A091990's forecast earnings growth (63.3% per year) is above the savings rate (2.3%).

Earnings vs Market: A091990's earnings (63.3% per year) are forecast to grow faster than the KR market (31.8% per year).

High Growth Earnings: A091990's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: A091990's revenue (17.2% per year) is forecast to grow faster than the KR market (9.4% per year).

High Growth Revenue: A091990's revenue (17.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A091990's Return on Equity is forecast to be low in 3 years time (13.7%).

Celltrion Healthcare Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 11%

Consensus forecasts updated

Consensus EPS estimates fall by 19%

Price target increased to ₩83,571

Consensus forecasts updated

Price target increased to ₩75,167

Recent updates

Celltrion Healthcare Co., Ltd.(KOSDAQ:A091990) dropped from FTSE All-World Index (USD)

Third quarter 2023 earnings released: EPS: ₩281 (vs ₩853 in 3Q 2022)

Celltrion Healthcare Presents Phase III Data from the LIBERTY-CD and LIBERTY-UC Clinical Trials

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

Consensus EPS estimates fall by 11%

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 15%

Upcoming dividend of ₩130 per share

Consensus forecasts updated

Consensus EPS estimates fall by 19%

European Commission Approves Celltrion Healthcare’s Vegzelma (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer

Price target increased to ₩83,571

Consensus forecasts updated

Price target increased to ₩75,167

Price target decreased to ₩69,333

Price target decreased to ₩78,311

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Celltrion Group Announces Positive Results for Its Cocktail Therapy Candidates Including Neutralisation Data Against Omicron Variant

Price target decreased to ₩99,889

Celltrion Accelerates Development of Nebulised Cocktail Therapy (CT-P63 in Combination with CT-P59) Using Its Antibody Platform to Tackle New Covid-19 Variants

Price target decreased to ₩109,900

Price target decreased to ₩127,200

Investor sentiment deteriorated over the past week

Celltrion Receives Approval from Korean Ministry of Food and Drug Safety for regdanvimab

Consensus EPS estimates fall to ₩1,997

Celltrion’S Monoclonal Antibody Treatment for COVID-19, Regdanvimab, Demonstrates Strong Neutralising Activity Against Delta Variant

Celltrion Healthcare Announces Positive Top-Line Results from Global Phase III Trial of Regdanvimab (CT-P59), an Anti-Covid-19 Monoclonal Antibody Treatment

Celltrion Healthcare Presents Positive One-Year Data for YuflymaTM (Ct-P17)

Consensus EPS estimates fall to ₩2,086

Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)

Celltrion Healthcare Receives Positive Chmp Opinion for Subcutaneous Formulation of Infliximab, Remsima® Sc, for Direct Use of Subcutaneous Therapy Without Iv Loading in Adults with Rheumatoid Arthritis

New 90-day low: ₩120,700

Celltrion Healthcare Receives European Commission Approval for the First High Concentration, Low-Volume and Citrate-Free Biosimilar Adalimumab, YuflymaTM

Price target raised to ₩131,030

New 90-day high: ₩176,900

Celltrion Healthcare Receives EU CHMP Positive Opinion for Biosimilar Adalimumab, CT-P17

New 90-day high: ₩108,100

Celltrion Healthcare Presents Positive Top-Line Efficacy and Safety Results for CT-P17 in the Treatment of Rheumatoid Arthritis

New 90-day low: ₩84,700

Celltrion Initiates Post-Exposure Prophylaxis Clinical Trial of an Anti-COVID-19 Monoclonal Antibody Treatment Candidate, CT-P59

Celltrion Healthcare Announces Two New Data Sets Relating to the Use of the Subcutaneous Formulation of Infliximab, Remsima

New 90-day low: ₩94,200

Celltrion Receives Korean MFDS Approval to Initiate Phase Ii/Iii Pivotal Trial of an Anti-COVID-19 Monoclonal Antibody Treatment Candidate, CT-P59

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies